TABLE 1.

Phenotypic data for the E. coli and K. pneumoniae isolates studied during in vivo efficacy experiments^a

Isolate	MIC (mg/liter)
	FEP-AAIb					FEP	TZP	MEM	CIP	TOB
	1 mg/liter	2 mg/liter	4 mg/liter	8 mg/liter	16 mg/liter
K. pneumoniae C13-10c	32	16	8	2	0.13	64	>256	16	>16	32
K. pneumoniae C16-9d	>64	16	4	2	2	>64	>256	1	>16	16
K. pneumoniae C22-6	8	8	4	4	2	8	>256	0.25	4	0.5
E. coli C22-30c	32	32	32	4	0.5	32	>256	16	>64	16
E. coli C16-4c	>64	>64	64	8	1	>64	>256	16	1	64
K. pneumoniae C31-2c	>64	32	8	8	2	>64	>256	32	>16	>64
K. pneumoniae C31-14c	16	16	8	8	0.25	>64	>256	64	>16	0.5
K. pneumoniae C37-25c	64	32	32	8	1	>64	>256	32	>16	32
K. pneumoniae C4-25c	32	32	16	16	1	64	>256	64	>16	16
K. pneumoniae C21-22c	>64	>64	32	16	16	>64	>256	32	>64	32
K. pneumoniae C31-18c	>64	>64	64	16	0.5	>64	>256	32	>16	16
K. pneumoniae C37-28c	>64	>64	16	16	0.25	>64	>256	16	>16	16
K. pneumoniae C6-5c	>64	>64	64	32	1	>64	>256	32	>16	32
K. pneumoniae C13-25	32	32	32	32	4	>64	256	>64	2	16
K. pneumoniae C19-1c	64	64	64	32	2	>64	>256	16	>64	32
K. pneumoniae C30-5c	64	64	32	32	16	>64	>256	64	>16	32
E. coli C3-14	>64	>64	>64	64	1	>64	>256	4	4	64
K. pneumoniae C30-27c	>64	>64	>64	64	64	>64	>256	>64	>16	32
K. pneumoniae C4-10c	>64	>64	>64	>64	>64	>64	>256	>64	>16	32
K. pneumoniae C8-9c	>64	>64	>64	>64	64	>64	>256	>64	>16	32

^aFEP-AAI, cefepime-AAI101; CIP, ciprofloxacin; FEP, cefepime; MEM, meropenem; TOB, tobramycin; TZP, piperacillin-tazobactam.

^bThe fixed concentrations of AAI101 utilized during MIC determination are indicated.

^cCarbapenemase producer.

^dESBL producer.